5-R01-EB031935-04 |
A high-performance and versatile technology for precision microbiome engineering |
Harris Wang |
Columbia University Health Sciences |
5-R21-EB033595-02 |
A Molecular Grammar for Guide RNAs (gRNAs) with Engineered Secondary Structures |
Eric Josephs |
University of North Carolina Greensboro |
1-DP2-EB035891-01 |
A Novel Class of Synthetic Receptors to Empower the Age of mRNA Therapies |
Xiaojing Gao |
Stanford University |
1-R21-EB033459-01A1 |
A Novel Vector Platform to Actualize T Cell Modification In Vivo |
David Curiel |
Washington University |
5-R01-EB027895-05 |
Accelerating phage evolution and tools via synthetic biology and machine learning |
Sam Nugen |
Cornell University |
5-R21-EB032491-03 |
An Engineered CRISPR System for Boosting Tumor Immunogenicity. |
Weixin Tang |
University of Chicago |
5-R01-EB030015-04 |
Cell targeting with synthetic sense-and-respond protease circuits |
Michael Elowitz |
California Institute of Technology |
1-R21-EB035208-01A1 |
Computationally designed, small molecule-responsive cell receptors for treating solid tumors |
Anum Glasgow |
Columbia University Health Sciences |
1-R21-EB036298-01 |
Development of potent and safe CRISPR tools for in vivo gene editing using directed evolution |
Shannon Miller |
Scripps Research Institute, The |
5-R01-EB031124-04 |
Directed evolution of a sequence-specific targeting technology for therapeutic gene delivery to the human genome. |
Jesse Owens |
University of Hawaii at Manoa |